This inventor holds 1 USPTO granted patent and 1 published patent application, plus 2 CIPO patents and 1 EPO patent. Top assignees: Les Laboratoires Servier, Novartis Ag. Active years: 2022.
Company Filing History:
1 out of 296 
1 out of 3,975 
Years Active: 2022
Title: Donia Moujalled: Innovator in Hematologic Cancer Treatments
Introduction
Donia Moujalled is a notable inventor based in Lalor, Australia. He has made significant contributions to the field of hematologic cancers through his innovative research and development of pharmaceutical compositions.
Latest Patents
Moujalled holds a patent for a groundbreaking combination of a Mcl-1 inhibitor and a standard of care treatment for hematologic cancers. This patent, titled "Combination of a Mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof," involves a combination comprising a Mcl-1 inhibitor and a second anticancer agent. The second anticancer agent is selected from anthracyclines, cytarabine, and hypomethylating agents, along with the compositions and uses thereof. He has 1 patent to his name.
Career Highlights
Throughout his career, Donia Moujalled has worked with prominent companies in the pharmaceutical industry, including Les Laboratoires Servier and Novartis AG. His work has focused on developing effective treatments for cancer, showcasing his commitment to improving patient outcomes.
Collaborations
Moujalled has collaborated with esteemed colleagues in his field, including Andrew Wei and Giovanna Pomilio. Their combined expertise has contributed to advancements in cancer treatment research.
Conclusion
Donia Moujalled's innovative work in the field of hematologic cancers highlights his dedication to advancing medical science. His contributions through patents and collaborations continue to pave the way for new treatment options.